Molina Healthcare
MOH
$200.28
+3.17%
Molina Healthcare, Inc. is a managed healthcare company that provides medical insurance plans primarily through Medicaid, Medicare, and Marketplace segments, serving over 5 million members, with a strong focus on government-sponsored programs. As a leading Medicaid managed care provider, Molina differentiates itself through its deep state contract relationships, with four states—California, New York, Texas, and Washington—accounting for over half of its enrollees. The current investor narrative centers on the company's recovery from a challenging 2025, marked by margin pressures and a recent quarterly loss, while a favorable CMS Medicare payment increase for 2027 has boosted sector sentiment and raised expectations for improved revenue visibility and profitability.…
MOH
Molina Healthcare
$200.28
Investment Opinion: Should I buy MOH Today?
Based on the analysis, I rate Molina Healthcare as a Hold. The stock has strong momentum and a favorable regulatory catalyst, but the fundamental challenges of declining revenue and thin margins warrant caution. The analyst consensus is neutral, with an average target price of $209.12, implying only 4.56% upside, which does not provide a compelling risk-reward for new buyers.
Sign up to view all
MOH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Molina's valuation is attractive on a PS basis, but the company faces significant operational headwinds, including declining revenue and razor-thin margins. The CMS payment increase is a positive for 2027, but near-term risks remain. The stock's momentum is strong, but the fundamental picture is mixed. To upgrade to bullish, we would need to see evidence of margin recovery and revenue stabilization; to downgrade to bearish, we would need to see further deterioration in earnings or a breach of debt covenants.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Molina Healthcare's 12-month outlook, with a consensus price target around $209.12 and implied upside of +4.4% versus the current price.
Average Target
$209.12
0 analysts
Implied Upside
+4.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$147 - $266
Analyst target range
Molina is covered by 17 analysts, with a consensus recommendation leaning neutral, as recent ratings from major firms like TD Cowen, Truist, and Wells Fargo are all 'Hold' or 'Equal Weight', and Barclays maintains an 'Underweight'. The average target price is $209.12, implying a modest 4.56% upside from the current price of $200.00, while the low target of $147.00 suggests a potential 26.5% downside, and the high target of $266.00 offers a 33% upside. The wide range between low and high targets indicates significant uncertainty, likely due to regulatory and margin volatility, while the recent ratings show no upgrades or downgrades, reflecting a stable but cautious outlook.
Bulls vs Bears: MOH Investment Factors
Molina Healthcare presents a mixed picture: the stock has strong momentum and a favorable regulatory catalyst from CMS, but fundamental challenges persist, including declining revenue, compressed margins, and high leverage. The bull case hinges on the CMS payment increase driving margin recovery and membership growth, while the bear case centers on continued operational headwinds and a leveraged balance sheet. Currently, the bearish evidence is slightly stronger due to the recent revenue decline and thin margins, but the stock's low valuation and positive regulatory news provide a counterbalance. The most critical tension is whether the company can translate the CMS tailwind into sustained profitability, which would validate the recent rally and support further upside.
Bullish
- Favorable CMS Medicare Payment Increase: The CMS announced a larger-than-expected 2027 Medicare Advantage payment increase, boosting revenue visibility and sentiment across the managed care sector. This directly benefits Molina's Medicare segment, which generated $1.517 billion in Q1 2026 revenue, and could drive improved profitability and growth.
- Strong Recent Stock Momentum: Molina's stock has rallied 29.83% over the past 6 months and 15.21% over the past 3 months, outperforming the S&P 500's 12.15% and 1.7% gains over the same periods. This momentum reflects improving investor confidence and a recovery from the 2025 lows.
- Undervalued on Price-to-Sales: With a PS ratio of 0.19x, Molina trades at a significant discount to the industry average, suggesting the market is pricing in low margins but also presenting a potential value opportunity. This low multiple could attract value investors if earnings stabilize.
- Analyst High Target Offers Upside: The analyst high target price of $266.00 implies a 33% upside from the current price of $200.00. While the average target is only $209.12, the high target suggests that some analysts see substantial recovery potential if the company executes well.
Bearish
- Revenue Declining Year-Over-Year: Q1 2026 revenue of $10.796 billion declined 3.15% year-over-year from $11.147 billion in Q1 2025, breaking a streak of sequential growth. This contraction may be due to Medicaid redeterminations or membership losses, raising concerns about top-line sustainability.
- Margins Under Severe Pressure: Operating margin in Q1 2026 was only 1.63%, down from 3.88% in Q1 2025, and net margin was a razor-thin 0.13%. The company reported a net loss in Q4 2025, and the recent quarterly loss highlights ongoing profitability challenges.
- High Debt-to-Equity Ratio: Molina's debt-to-equity ratio stands at 0.97, indicating a highly leveraged balance sheet. This increases financial risk, especially if interest rates remain elevated or if earnings continue to be volatile.
- Analyst Sentiment Cautious: The consensus recommendation is neutral, with recent ratings from TD Cowen, Truist, and Wells Fargo all 'Hold' or 'Equal Weight', and Barclays maintaining 'Underweight'. The average target price of $209.12 implies only 4.56% upside, reflecting limited confidence in near-term appreciation.
MOH Technical Analysis
Molina's stock has demonstrated a strong recovery over the past year, with a 1-year price change of +14.47%, though it lags the S&P 500's +18.56% gain. Currently trading at $200.00, the stock sits at 81.8% of its 52-week range (between $121.06 low and $244.89 high), indicating a position closer to the highs, suggesting positive momentum but also potential overextension after a significant rally. The 6-month change of +29.83% and 3-month change of +15.21% highlight a robust upward trend, though the stock has pulled back from its July peak of $244.89, reflecting some consolidation.
Beta
0.76
0.76x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$121-$245
Price range past year
Annual Return
+11.8%
Cumulative gain past year
| Period | MOH Return | S&P 500 |
|---|---|---|
| 1m | +3.0% | -1.6% |
| 3m | +0.0% | +2.2% |
| 6m | +34.2% | +14.4% |
| 1y | +11.8% | +16.2% |
| ytd | +12.2% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOH Fundamental Analysis
Revenue in Q1 2026 was $10.796 billion, a 3.15% decline year-over-year from $11.147 billion in Q1 2025, breaking a streak of sequential growth seen in 2024 and early 2025. The revenue trajectory has been volatile, with Q4 2025 at $11.375 billion and Q3 2025 at $11.477 billion, but the latest quarter shows a contraction, possibly due to Medicaid redeterminations or membership changes. Segment data reveals Medicaid Solutions as the dominant driver at $7.927 billion, followed by Medicare at $1.517 billion and Marketplace at $724 million, indicating reliance on government contracts.
Quarterly Revenue
$10.8B
2026-03
Revenue YoY Growth
-3.1%
YoY Comparison
Gross Margin
9.5%
Latest Quarter
Free Cash Flow
$251000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOH Overvalued?
Given positive trailing net income of $14 million in Q1 2026, the PE ratio is the primary valuation metric. The trailing PE is 19.43x, while the forward PE is 20.53x, implying a slight premium on forward earnings, which suggests the market expects earnings growth to moderate or that current earnings are temporarily depressed. The stock's PS ratio of 0.19x is significantly lower than the industry average, indicating a potential value opportunity relative to sales, but this is typical for managed care companies with thin margins.
PE
19.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant: Molina's net income in Q1 2026 was a mere $14 million on $10.8 billion in revenue, reflecting a net margin of 0.13%, down from 2.67% a year earlier. The company also reported a net loss of $160 million in Q4 2025, indicating earnings volatility. With a debt-to-equity ratio of 0.97, the balance sheet is highly leveraged, and interest expenses of $54 million in Q1 2026 add to the burden. Free cash flow is positive but modest at $251 million TTM, limiting financial flexibility. Revenue concentration in government programs (Medicaid, Medicare) exposes the company to policy changes and reimbursement rate adjustments, which can abruptly impact profitability.